Lilly to acquire ImClone; Bristol abandons buyout bid

10/6/2008 | Bloomberg · Reuters

Eli Lilly and Co. confirmed that it will pay $6.5 billion to take over ImClone Systems, maker of cancer treatment Erbitux. The move allows Lilly to expand its pipeline as it prepares to counter generic competition for Zyprexa, a top-selling schizophrenia drug. Bristol-Myers Squibb said it expects to get about $1 billion by selling its shares in ImClone, but it will continue to co-market Erbitux in the U.S.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA